Somatic	O
molecular	B:C0022885
subtyping	I:C0022885
of	O
prostate	O
tumors	I:C0033578
from	O
HOXB13	O
G84E	O
carriers	I:C0206530
A	O
recurrent	O
germline	O
mutation	I:C0206530
(	I:C0206530
G84E	I:C0206530
)	I:C0206530
in	O
the	O
HOXB13	O
gene	I:C1415664
is	O
associated	O
with	O
early	O
onset	I:C1833334
and	O
family	O
history	I:C0241889
-	O
positive	O
prostate	O
cancer	I:C0600139
in	O
patients	O
of	O
European	O
descent	I:C1535514
,	O
occurring	O
in	O
up	O
to	O
5	O
%	O
of	O
prostate	O
cancer	I:C0600139
families	O
.	O

Somatic	O
molecular	O
subtyping	I:C0022885
of	O
prostate	B:C0033578
tumors	I:C0033578
from	O
HOXB13	O
G84E	O
carriers	I:C0206530
A	O
recurrent	O
germline	O
mutation	I:C0206530
(	I:C0206530
G84E	I:C0206530
)	I:C0206530
in	O
the	O
HOXB13	O
gene	I:C1415664
is	O
associated	O
with	O
early	O
onset	I:C1833334
and	O
family	O
history	I:C0241889
-	O
positive	O
prostate	O
cancer	I:C0600139
in	O
patients	O
of	O
European	O
descent	I:C1535514
,	O
occurring	O
in	O
up	O
to	O
5	O
%	O
of	O
prostate	O
cancer	I:C0600139
families	O
.	O

Somatic	O
molecular	O
subtyping	I:C0022885
of	O
prostate	O
tumors	I:C0033578
from	O
HOXB13	B:C1415664
G84E	O
carriers	I:C0206530
A	O
recurrent	O
germline	O
mutation	I:C0206530
(	I:C0206530
G84E	I:C0206530
)	I:C0206530
in	O
the	O
HOXB13	O
gene	I:C1415664
is	O
associated	O
with	O
early	O
onset	I:C1833334
and	O
family	O
history	I:C0241889
-	O
positive	O
prostate	O
cancer	I:C0600139
in	O
patients	O
of	O
European	O
descent	I:C1535514
,	O
occurring	O
in	O
up	O
to	O
5	O
%	O
of	O
prostate	O
cancer	I:C0600139
families	O
.	O

Somatic	O
molecular	O
subtyping	I:C0022885
of	O
prostate	O
tumors	I:C0033578
from	O
HOXB13	O
G84E	B:C0206530
carriers	I:C0206530
A	O
recurrent	O
germline	O
mutation	I:C0206530
(	I:C0206530
G84E	I:C0206530
)	I:C0206530
in	O
the	O
HOXB13	O
gene	I:C1415664
is	O
associated	O
with	O
early	O
onset	I:C1833334
and	O
family	O
history	I:C0241889
-	O
positive	O
prostate	O
cancer	I:C0600139
in	O
patients	O
of	O
European	O
descent	I:C1535514
,	O
occurring	O
in	O
up	O
to	O
5	O
%	O
of	O
prostate	O
cancer	I:C0600139
families	O
.	O

Somatic	O
molecular	O
subtyping	I:C0022885
of	O
prostate	O
tumors	I:C0033578
from	O
HOXB13	O
G84E	O
carriers	I:C0206530
A	O
recurrent	O
germline	B:C0206530
mutation	I:C0206530
(	I:C0206530
G84E	I:C0206530
)	I:C0206530
in	O
the	O
HOXB13	O
gene	I:C1415664
is	O
associated	O
with	O
early	O
onset	I:C1833334
and	O
family	O
history	I:C0241889
-	O
positive	O
prostate	O
cancer	I:C0600139
in	O
patients	O
of	O
European	O
descent	I:C1535514
,	O
occurring	O
in	O
up	O
to	O
5	O
%	O
of	O
prostate	O
cancer	I:C0600139
families	O
.	O

Somatic	O
molecular	O
subtyping	I:C0022885
of	O
prostate	O
tumors	I:C0033578
from	O
HOXB13	O
G84E	O
carriers	I:C0206530
A	O
recurrent	O
germline	O
mutation	I:C0206530
(	I:C0206530
G84E	I:C0206530
)	I:C0206530
in	O
the	O
HOXB13	B:C1415664
gene	I:C1415664
is	O
associated	O
with	O
early	O
onset	I:C1833334
and	O
family	O
history	I:C0241889
-	O
positive	O
prostate	O
cancer	I:C0600139
in	O
patients	O
of	O
European	O
descent	I:C1535514
,	O
occurring	O
in	O
up	O
to	O
5	O
%	O
of	O
prostate	O
cancer	I:C0600139
families	O
.	O

Somatic	O
molecular	O
subtyping	I:C0022885
of	O
prostate	O
tumors	I:C0033578
from	O
HOXB13	O
G84E	O
carriers	I:C0206530
A	O
recurrent	O
germline	O
mutation	I:C0206530
(	I:C0206530
G84E	I:C0206530
)	I:C0206530
in	O
the	O
HOXB13	O
gene	I:C1415664
is	O
associated	O
with	O
early	B:C1833334
onset	I:C1833334
and	O
family	O
history	I:C0241889
-	O
positive	O
prostate	O
cancer	I:C0600139
in	O
patients	O
of	O
European	O
descent	I:C1535514
,	O
occurring	O
in	O
up	O
to	O
5	O
%	O
of	O
prostate	O
cancer	I:C0600139
families	O
.	O

Somatic	O
molecular	O
subtyping	I:C0022885
of	O
prostate	O
tumors	I:C0033578
from	O
HOXB13	O
G84E	O
carriers	I:C0206530
A	O
recurrent	O
germline	O
mutation	I:C0206530
(	I:C0206530
G84E	I:C0206530
)	I:C0206530
in	O
the	O
HOXB13	O
gene	I:C1415664
is	O
associated	O
with	O
early	O
onset	I:C1833334
and	O
family	B:C0241889
history	I:C0241889
-	O
positive	O
prostate	O
cancer	I:C0600139
in	O
patients	O
of	O
European	O
descent	I:C1535514
,	O
occurring	O
in	O
up	O
to	O
5	O
%	O
of	O
prostate	O
cancer	I:C0600139
families	O
.	O

Somatic	O
molecular	O
subtyping	I:C0022885
of	O
prostate	O
tumors	I:C0033578
from	O
HOXB13	O
G84E	O
carriers	I:C0206530
A	O
recurrent	O
germline	O
mutation	I:C0206530
(	I:C0206530
G84E	I:C0206530
)	I:C0206530
in	O
the	O
HOXB13	O
gene	I:C1415664
is	O
associated	O
with	O
early	O
onset	I:C1833334
and	O
family	O
history	I:C0241889
-	O
positive	O
prostate	B:C0600139
cancer	I:C0600139
in	O
patients	O
of	O
European	O
descent	I:C1535514
,	O
occurring	O
in	O
up	O
to	O
5	O
%	O
of	O
prostate	O
cancer	I:C0600139
families	O
.	O

Somatic	O
molecular	O
subtyping	I:C0022885
of	O
prostate	O
tumors	I:C0033578
from	O
HOXB13	O
G84E	O
carriers	I:C0206530
A	O
recurrent	O
germline	O
mutation	I:C0206530
(	I:C0206530
G84E	I:C0206530
)	I:C0206530
in	O
the	O
HOXB13	O
gene	I:C1415664
is	O
associated	O
with	O
early	O
onset	I:C1833334
and	O
family	O
history	I:C0241889
-	O
positive	O
prostate	O
cancer	I:C0600139
in	O
patients	O
of	O
European	B:C1535514
descent	I:C1535514
,	O
occurring	O
in	O
up	O
to	O
5	O
%	O
of	O
prostate	O
cancer	I:C0600139
families	O
.	O

Somatic	O
molecular	O
subtyping	I:C0022885
of	O
prostate	O
tumors	I:C0033578
from	O
HOXB13	O
G84E	O
carriers	I:C0206530
A	O
recurrent	O
germline	O
mutation	I:C0206530
(	I:C0206530
G84E	I:C0206530
)	I:C0206530
in	O
the	O
HOXB13	O
gene	I:C1415664
is	O
associated	O
with	O
early	O
onset	I:C1833334
and	O
family	O
history	I:C0241889
-	O
positive	O
prostate	O
cancer	I:C0600139
in	O
patients	O
of	O
European	O
descent	I:C1535514
,	O
occurring	O
in	O
up	O
to	O
5	O
%	O
of	O
prostate	B:C0600139
cancer	I:C0600139
families	O
.	O

To	O
date	O
,	O
the	O
molecular	B:C0026383
features	I:C0026383
of	O
prostate	O
tumors	I:C0033578
occurring	O
in	O
HOXB13	O
G84E	O
carriers	I:C0206530
have	O
not	O
been	O
studied	O
in	O
a	O
large	O
cohort	O
of	O
patients	O
.	O

To	O
date	O
,	O
the	O
molecular	O
features	I:C0026383
of	O
prostate	B:C0033578
tumors	I:C0033578
occurring	O
in	O
HOXB13	O
G84E	O
carriers	I:C0206530
have	O
not	O
been	O
studied	O
in	O
a	O
large	O
cohort	O
of	O
patients	O
.	O

To	O
date	O
,	O
the	O
molecular	O
features	I:C0026383
of	O
prostate	O
tumors	I:C0033578
occurring	O
in	O
HOXB13	B:C1415664
G84E	O
carriers	I:C0206530
have	O
not	O
been	O
studied	O
in	O
a	O
large	O
cohort	O
of	O
patients	O
.	O

To	O
date	O
,	O
the	O
molecular	O
features	I:C0026383
of	O
prostate	O
tumors	I:C0033578
occurring	O
in	O
HOXB13	O
G84E	B:C0206530
carriers	I:C0206530
have	O
not	O
been	O
studied	O
in	O
a	O
large	O
cohort	O
of	O
patients	O
.	O

We	O
identified	O
101	O
heterozygous	B:C0206530
carriers	I:C0206530
of	I:C0206530
G84E	I:C0206530
who	O
underwent	O
radical	O
prostatectomy	I:C0194810
for	O
prostate	O
cancer	I:C0600139
between	O
1985	O
and	O
2011	O
and	O
matched	O
these	O
men	O
by	O
race	O
,	O
age	O
and	O
tumor	O
grade	I:C0027651
to	O
99	O
HOXB13	O
wild	O
-	I:C1883559
type	I:C1883559
controls	O
.	O

We	O
identified	O
101	O
heterozygous	O
carriers	I:C0206530
of	I:C0206530
G84E	I:C0206530
who	O
underwent	O
radical	B:C0194810
prostatectomy	I:C0194810
for	O
prostate	O
cancer	I:C0600139
between	O
1985	O
and	O
2011	O
and	O
matched	O
these	O
men	O
by	O
race	O
,	O
age	O
and	O
tumor	O
grade	I:C0027651
to	O
99	O
HOXB13	O
wild	O
-	I:C1883559
type	I:C1883559
controls	O
.	O

We	O
identified	O
101	O
heterozygous	O
carriers	I:C0206530
of	I:C0206530
G84E	I:C0206530
who	O
underwent	O
radical	O
prostatectomy	I:C0194810
for	O
prostate	B:C0600139
cancer	I:C0600139
between	O
1985	O
and	O
2011	O
and	O
matched	O
these	O
men	O
by	O
race	O
,	O
age	O
and	O
tumor	O
grade	I:C0027651
to	O
99	O
HOXB13	O
wild	O
-	I:C1883559
type	I:C1883559
controls	O
.	O

We	O
identified	O
101	O
heterozygous	O
carriers	I:C0206530
of	I:C0206530
G84E	I:C0206530
who	O
underwent	O
radical	O
prostatectomy	I:C0194810
for	O
prostate	O
cancer	I:C0600139
between	O
1985	O
and	O
2011	O
and	O
matched	O
these	O
men	O
by	O
race	B:C0034510
,	O
age	O
and	O
tumor	O
grade	I:C0027651
to	O
99	O
HOXB13	O
wild	O
-	I:C1883559
type	I:C1883559
controls	O
.	O

We	O
identified	O
101	O
heterozygous	O
carriers	I:C0206530
of	I:C0206530
G84E	I:C0206530
who	O
underwent	O
radical	O
prostatectomy	I:C0194810
for	O
prostate	O
cancer	I:C0600139
between	O
1985	O
and	O
2011	O
and	O
matched	O
these	O
men	O
by	O
race	O
,	O
age	O
and	O
tumor	B:C0027651
grade	I:C0027651
to	O
99	O
HOXB13	O
wild	O
-	I:C1883559
type	I:C1883559
controls	O
.	O

We	O
identified	O
101	O
heterozygous	O
carriers	I:C0206530
of	I:C0206530
G84E	I:C0206530
who	O
underwent	O
radical	O
prostatectomy	I:C0194810
for	O
prostate	O
cancer	I:C0600139
between	O
1985	O
and	O
2011	O
and	O
matched	O
these	O
men	O
by	O
race	O
,	O
age	O
and	O
tumor	O
grade	I:C0027651
to	O
99	O
HOXB13	B:C1415664
wild	O
-	I:C1883559
type	I:C1883559
controls	O
.	O

We	O
identified	O
101	O
heterozygous	O
carriers	I:C0206530
of	I:C0206530
G84E	I:C0206530
who	O
underwent	O
radical	O
prostatectomy	I:C0194810
for	O
prostate	O
cancer	I:C0600139
between	O
1985	O
and	O
2011	O
and	O
matched	O
these	O
men	O
by	O
race	O
,	O
age	O
and	O
tumor	O
grade	I:C0027651
to	O
99	O
HOXB13	O
wild	B:C1883559
-	I:C1883559
type	I:C1883559
controls	O
.	O

Immunostaining	B:C0022885
for	O
HOXB13	O
,	O
PTEN	O
,	O
ERG	O
,	O
p53	O
and	O
SPINK1	O
as	O
well	O
as	O
RNA	O
in	O
situ	I:C0162788
hybridization	I:C0162788
for	O
ETV1	O
/	O
4	O
/	O
5	O
were	O
performed	O
using	O
genetically	O
validated	I:C0005507
assays	I:C0005507
.	O

Immunostaining	O
for	O
HOXB13	B:C1436058
,	O
PTEN	O
,	O
ERG	O
,	O
p53	O
and	O
SPINK1	O
as	O
well	O
as	O
RNA	O
in	O
situ	I:C0162788
hybridization	I:C0162788
for	O
ETV1	O
/	O
4	O
/	O
5	O
were	O
performed	O
using	O
genetically	O
validated	I:C0005507
assays	I:C0005507
.	O

Immunostaining	O
for	O
HOXB13	O
,	O
PTEN	B:C1430988
,	O
ERG	O
,	O
p53	O
and	O
SPINK1	O
as	O
well	O
as	O
RNA	O
in	O
situ	I:C0162788
hybridization	I:C0162788
for	O
ETV1	O
/	O
4	O
/	O
5	O
were	O
performed	O
using	O
genetically	O
validated	I:C0005507
assays	I:C0005507
.	O

Immunostaining	O
for	O
HOXB13	O
,	O
PTEN	O
,	O
ERG	B:C0295291
,	O
p53	O
and	O
SPINK1	O
as	O
well	O
as	O
RNA	O
in	O
situ	I:C0162788
hybridization	I:C0162788
for	O
ETV1	O
/	O
4	O
/	O
5	O
were	O
performed	O
using	O
genetically	O
validated	I:C0005507
assays	I:C0005507
.	O

Immunostaining	O
for	O
HOXB13	O
,	O
PTEN	O
,	O
ERG	O
,	O
p53	B:C0080055
and	O
SPINK1	O
as	O
well	O
as	O
RNA	O
in	O
situ	I:C0162788
hybridization	I:C0162788
for	O
ETV1	O
/	O
4	O
/	O
5	O
were	O
performed	O
using	O
genetically	O
validated	I:C0005507
assays	I:C0005507
.	O

Immunostaining	O
for	O
HOXB13	O
,	O
PTEN	O
,	O
ERG	O
,	O
p53	O
and	O
SPINK1	B:C1452174
as	O
well	O
as	O
RNA	O
in	O
situ	I:C0162788
hybridization	I:C0162788
for	O
ETV1	O
/	O
4	O
/	O
5	O
were	O
performed	O
using	O
genetically	O
validated	I:C0005507
assays	I:C0005507
.	O

Immunostaining	O
for	O
HOXB13	O
,	O
PTEN	O
,	O
ERG	O
,	O
p53	O
and	O
SPINK1	O
as	O
well	O
as	O
RNA	B:C0035668
in	O
situ	I:C0162788
hybridization	I:C0162788
for	O
ETV1	O
/	O
4	O
/	O
5	O
were	O
performed	O
using	O
genetically	O
validated	I:C0005507
assays	I:C0005507
.	O

Immunostaining	O
for	O
HOXB13	O
,	O
PTEN	O
,	O
ERG	O
,	O
p53	O
and	O
SPINK1	O
as	O
well	O
as	O
RNA	O
in	B:C0162788
situ	I:C0162788
hybridization	I:C0162788
for	O
ETV1	O
/	O
4	O
/	O
5	O
were	O
performed	O
using	O
genetically	O
validated	I:C0005507
assays	I:C0005507
.	O

Immunostaining	O
for	O
HOXB13	O
,	O
PTEN	O
,	O
ERG	O
,	O
p53	O
and	O
SPINK1	O
as	O
well	O
as	O
RNA	O
in	O
situ	I:C0162788
hybridization	I:C0162788
for	O
ETV1	B:C1333361
/	O
4	O
/	O
5	O
were	O
performed	O
using	O
genetically	O
validated	I:C0005507
assays	I:C0005507
.	O

Immunostaining	O
for	O
HOXB13	O
,	O
PTEN	O
,	O
ERG	O
,	O
p53	O
and	O
SPINK1	O
as	O
well	O
as	O
RNA	O
in	O
situ	I:C0162788
hybridization	I:C0162788
for	O
ETV1	O
/	O
4	B:C1333362
/	O
5	O
were	O
performed	O
using	O
genetically	O
validated	I:C0005507
assays	I:C0005507
.	O

Immunostaining	O
for	O
HOXB13	O
,	O
PTEN	O
,	O
ERG	O
,	O
p53	O
and	O
SPINK1	O
as	O
well	O
as	O
RNA	O
in	O
situ	I:C0162788
hybridization	I:C0162788
for	O
ETV1	O
/	O
4	O
/	O
5	B:C1414477
were	O
performed	O
using	O
genetically	O
validated	I:C0005507
assays	I:C0005507
.	O

Immunostaining	O
for	O
HOXB13	O
,	O
PTEN	O
,	O
ERG	O
,	O
p53	O
and	O
SPINK1	O
as	O
well	O
as	O
RNA	O
in	O
situ	I:C0162788
hybridization	I:C0162788
for	O
ETV1	O
/	O
4	O
/	O
5	O
were	O
performed	O
using	O
genetically	B:C0005507
validated	I:C0005507
assays	I:C0005507
.	O

Tumors	B:C0027651
from	O
G84E	O
carriers	I:C0206530
generally	O
expressed	O
HOXB13	O
protein	I:C1436058
at	O
a	O
level	O
comparable	O
to	O
benign	O
and	O
wild	O
-	I:C1883559
type	I:C1883559
glands	O
.	O

Tumors	O
from	O
G84E	B:C0206530
carriers	I:C0206530
generally	O
expressed	O
HOXB13	O
protein	I:C1436058
at	O
a	O
level	O
comparable	O
to	O
benign	O
and	O
wild	O
-	I:C1883559
type	I:C1883559
glands	O
.	O

Tumors	O
from	O
G84E	O
carriers	I:C0206530
generally	O
expressed	B:C1171362
HOXB13	O
protein	I:C1436058
at	O
a	O
level	O
comparable	O
to	O
benign	O
and	O
wild	O
-	I:C1883559
type	I:C1883559
glands	O
.	O

Tumors	O
from	O
G84E	O
carriers	I:C0206530
generally	O
expressed	O
HOXB13	B:C1436058
protein	I:C1436058
at	O
a	O
level	O
comparable	O
to	O
benign	O
and	O
wild	O
-	I:C1883559
type	I:C1883559
glands	O
.	O

Tumors	O
from	O
G84E	O
carriers	I:C0206530
generally	O
expressed	O
HOXB13	O
protein	I:C1436058
at	O
a	O
level	O
comparable	O
to	O
benign	O
and	O
wild	B:C1883559
-	I:C1883559
type	I:C1883559
glands	O
.	O

ETS	B:C0812380
gene	O
expression	I:C0017262
(	O
either	O
ERG	O
or	O
ETV1	O
/	O
4	O
/	O
5	O
)	O
was	O
seen	O
in	O
36	O
%	O
(	O
36/101	O
)	O
of	O
tumors	O
from	O
G84E	O
carriers	I:C0206530
compared	O
to	O
68	O
%	O
(	O
65/96	O
)	O
of	O
the	O
controls	O
(	O
p	O
<	O
0.0001	O
)	O
.	O

ETS	O
gene	B:C0017262
expression	I:C0017262
(	O
either	O
ERG	O
or	O
ETV1	O
/	O
4	O
/	O
5	O
)	O
was	O
seen	O
in	O
36	O
%	O
(	O
36/101	O
)	O
of	O
tumors	O
from	O
G84E	O
carriers	I:C0206530
compared	O
to	O
68	O
%	O
(	O
65/96	O
)	O
of	O
the	O
controls	O
(	O
p	O
<	O
0.0001	O
)	O
.	O

ETS	O
gene	O
expression	I:C0017262
(	O
either	O
ERG	B:C0599295
or	O
ETV1	O
/	O
4	O
/	O
5	O
)	O
was	O
seen	O
in	O
36	O
%	O
(	O
36/101	O
)	O
of	O
tumors	O
from	O
G84E	O
carriers	I:C0206530
compared	O
to	O
68	O
%	O
(	O
65/96	O
)	O
of	O
the	O
controls	O
(	O
p	O
<	O
0.0001	O
)	O
.	O

ETS	O
gene	O
expression	I:C0017262
(	O
either	O
ERG	O
or	O
ETV1	B:C1333361
/	O
4	O
/	O
5	O
)	O
was	O
seen	O
in	O
36	O
%	O
(	O
36/101	O
)	O
of	O
tumors	O
from	O
G84E	O
carriers	I:C0206530
compared	O
to	O
68	O
%	O
(	O
65/96	O
)	O
of	O
the	O
controls	O
(	O
p	O
<	O
0.0001	O
)	O
.	O

ETS	O
gene	O
expression	I:C0017262
(	O
either	O
ERG	O
or	O
ETV1	O
/	O
4	B:C1333362
/	O
5	O
)	O
was	O
seen	O
in	O
36	O
%	O
(	O
36/101	O
)	O
of	O
tumors	O
from	O
G84E	O
carriers	I:C0206530
compared	O
to	O
68	O
%	O
(	O
65/96	O
)	O
of	O
the	O
controls	O
(	O
p	O
<	O
0.0001	O
)	O
.	O

ETS	O
gene	O
expression	I:C0017262
(	O
either	O
ERG	O
or	O
ETV1	O
/	O
4	O
/	O
5	B:C1414477
)	O
was	O
seen	O
in	O
36	O
%	O
(	O
36/101	O
)	O
of	O
tumors	O
from	O
G84E	O
carriers	I:C0206530
compared	O
to	O
68	O
%	O
(	O
65/96	O
)	O
of	O
the	O
controls	O
(	O
p	O
<	O
0.0001	O
)	O
.	O

ETS	O
gene	O
expression	I:C0017262
(	O
either	O
ERG	O
or	O
ETV1	O
/	O
4	O
/	O
5	O
)	O
was	O
seen	O
in	O
36	O
%	O
(	O
36/101	O
)	O
of	O
tumors	B:C0027651
from	O
G84E	O
carriers	I:C0206530
compared	O
to	O
68	O
%	O
(	O
65/96	O
)	O
of	O
the	O
controls	O
(	O
p	O
<	O
0.0001	O
)	O
.	O

ETS	O
gene	O
expression	I:C0017262
(	O
either	O
ERG	O
or	O
ETV1	O
/	O
4	O
/	O
5	O
)	O
was	O
seen	O
in	O
36	O
%	O
(	O
36/101	O
)	O
of	O
tumors	O
from	O
G84E	B:C0206530
carriers	I:C0206530
compared	O
to	O
68	O
%	O
(	O
65/96	O
)	O
of	O
the	O
controls	O
(	O
p	O
<	O
0.0001	O
)	O
.	O

PTEN	B:C1430988
was	O
lost	O
in	O
11	O
%	O
(	O
11/101	O
)	O
of	O
G84E	O
carriers	I:C0206530
compared	O
to	O
25	O
%	O
(	O
25/99	O
)	O
of	O
the	O
controls	O
(	O
p	O
=	O
0.014	O
)	O
.	O

PTEN	O
was	O
lost	O
in	O
11	O
%	O
(	O
11/101	O
)	O
of	O
G84E	B:C0206530
carriers	I:C0206530
compared	O
to	O
25	O
%	O
(	O
25/99	O
)	O
of	O
the	O
controls	O
(	O
p	O
=	O
0.014	O
)	O
.	O

PTEN	B:C1430988
loss	O
was	O
enriched	O
among	O
ERG	O
-	O
positive	O
compared	O
to	O
ERG	O
-	O
negative	O
tumors	O
in	O
both	O
groups	O
of	O
patients	O
.	O

PTEN	O
loss	O
was	O
enriched	O
among	O
ERG	B:C0295291
-	O
positive	O
compared	O
to	O
ERG	O
-	O
negative	O
tumors	O
in	O
both	O
groups	O
of	O
patients	O
.	O

PTEN	O
loss	O
was	O
enriched	O
among	O
ERG	O
-	O
positive	B:C1446409
compared	O
to	O
ERG	O
-	O
negative	O
tumors	O
in	O
both	O
groups	O
of	O
patients	O
.	O

PTEN	O
loss	O
was	O
enriched	O
among	O
ERG	O
-	O
positive	O
compared	O
to	O
ERG	B:C0295291
-	O
negative	O
tumors	O
in	O
both	O
groups	O
of	O
patients	O
.	O

PTEN	O
loss	O
was	O
enriched	O
among	O
ERG	O
-	O
positive	O
compared	O
to	O
ERG	O
-	O
negative	B:C0205160
tumors	O
in	O
both	O
groups	O
of	O
patients	O
.	O

PTEN	O
loss	O
was	O
enriched	O
among	O
ERG	O
-	O
positive	O
compared	O
to	O
ERG	O
-	O
negative	O
tumors	B:C0027651
in	O
both	O
groups	O
of	O
patients	O
.	O

Nuclear	O
accumulation	O
of	O
the	O
p53	B:C0080055
protein	I:C0080055
,	O
indicative	O
of	O
underlying	O
TP53	O
missense	O
mutations	I:C0599155
,	O
was	O
uncommon	O
in	O
both	O
groups	O
,	O
occurring	O
in	O
1	O
%	O
(	O
1/101	O
)	O
of	O
the	O
G84E	O
carriers	I:C0206530
versus	O
2	O
%	O
(	O
2/92	O
)	O
of	O
the	O
controls	O
(	O
p	O
=	O
NS	O
)	O
.	O

Nuclear	O
accumulation	O
of	O
the	O
p53	O
protein	I:C0080055
,	O
indicative	O
of	O
underlying	O
TP53	B:C0079419
missense	O
mutations	I:C0599155
,	O
was	O
uncommon	O
in	O
both	O
groups	O
,	O
occurring	O
in	O
1	O
%	O
(	O
1/101	O
)	O
of	O
the	O
G84E	O
carriers	I:C0206530
versus	O
2	O
%	O
(	O
2/92	O
)	O
of	O
the	O
controls	O
(	O
p	O
=	O
NS	O
)	O
.	O

Nuclear	O
accumulation	O
of	O
the	O
p53	O
protein	I:C0080055
,	O
indicative	O
of	O
underlying	O
TP53	O
missense	B:C0599155
mutations	I:C0599155
,	O
was	O
uncommon	O
in	O
both	O
groups	O
,	O
occurring	O
in	O
1	O
%	O
(	O
1/101	O
)	O
of	O
the	O
G84E	O
carriers	I:C0206530
versus	O
2	O
%	O
(	O
2/92	O
)	O
of	O
the	O
controls	O
(	O
p	O
=	O
NS	O
)	O
.	O

Nuclear	O
accumulation	O
of	O
the	O
p53	O
protein	I:C0080055
,	O
indicative	O
of	O
underlying	O
TP53	O
missense	O
mutations	I:C0599155
,	O
was	O
uncommon	O
in	O
both	O
groups	O
,	O
occurring	O
in	O
1	O
%	O
(	O
1/101	O
)	O
of	O
the	O
G84E	B:C0206530
carriers	I:C0206530
versus	O
2	O
%	O
(	O
2/92	O
)	O
of	O
the	O
controls	O
(	O
p	O
=	O
NS	O
)	O
.	O

Taken	O
together	O
,	O
these	O
data	O
suggest	O
that	O
genes	B:C0017337
other	O
than	O
ERG	O
and	O
PTEN	O
may	O
drive	O
carcinogenesis	O
/	O
progression	O
in	O
the	O
majority	O
of	O
men	O
with	O
germline	O
HOXB13	I:C0206530
mutations	I:C0206530
.	O

Taken	O
together	O
,	O
these	O
data	O
suggest	O
that	O
genes	O
other	O
than	O
ERG	B:C0599295
and	O
PTEN	O
may	O
drive	O
carcinogenesis	O
/	O
progression	O
in	O
the	O
majority	O
of	O
men	O
with	O
germline	O
HOXB13	I:C0206530
mutations	I:C0206530
.	O

Taken	O
together	O
,	O
these	O
data	O
suggest	O
that	O
genes	O
other	O
than	O
ERG	O
and	O
PTEN	B:C0694888
may	O
drive	O
carcinogenesis	O
/	O
progression	O
in	O
the	O
majority	O
of	O
men	O
with	O
germline	O
HOXB13	I:C0206530
mutations	I:C0206530
.	O

Taken	O
together	O
,	O
these	O
data	O
suggest	O
that	O
genes	O
other	O
than	O
ERG	O
and	O
PTEN	O
may	O
drive	O
carcinogenesis	B:C0596263
/	O
progression	O
in	O
the	O
majority	O
of	O
men	O
with	O
germline	O
HOXB13	I:C0206530
mutations	I:C0206530
.	O

Taken	O
together	O
,	O
these	O
data	O
suggest	O
that	O
genes	O
other	O
than	O
ERG	O
and	O
PTEN	O
may	O
drive	O
carcinogenesis	O
/	O
progression	O
in	O
the	O
majority	O
of	O
men	B:C0025266
with	O
germline	O
HOXB13	I:C0206530
mutations	I:C0206530
.	O

Taken	O
together	O
,	O
these	O
data	O
suggest	O
that	O
genes	O
other	O
than	O
ERG	O
and	O
PTEN	O
may	O
drive	O
carcinogenesis	O
/	O
progression	O
in	O
the	O
majority	O
of	O
men	O
with	O
germline	B:C0206530
HOXB13	I:C0206530
mutations	I:C0206530
.	O

